Blood tests

PreclinicalBiologic

RRennes University Hospital

Blood tests is one of 202 biologic programs targeting Cognitive Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

201

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive DisorderActive, not recruiting

IschemiaActive, not recruiting

Aortic StenosisActive, not recruiting

Ovarian ReserveActive, not recruiting

Cerebrotendinous XanthomatosisActive, not recruiting

COVID-19Active, not recruiting

Hidradenitis SuppurativaActive, not recruiting

Cognitive DisorderPreclinical

Active, not recruiting

IschemiaPreclinical

Active, not recruiting

Aortic StenosisPreclinical

Active, not recruiting

Ovarian ReservePreclinical

Active, not recruiting

Cerebrotendinous XanthomatosisPreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Hidradenitis SuppurativaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

Bnt162b2

BioNTech

Preclinical

29 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Biaxin

AbbVie

Preclinical

2 5

Aldactone

Pfizer

Preclinical

1 6

Nexavar

Bayer

Preclinical

1 7

Stivarga

Bayer

Preclinical

1 8

Aimovig

Amgen

Preclinical

1 9

Singulair

AstraZeneca

Preclinical

1 10

Calciferol

Alnylam Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cerebrotendinous Xanthomatosis1 trial

Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis

Unknown status·SSheba Medical Center··NCT01613898·17 enrolled

Ischemia1 trial

Evaluation of Oxiris Membrane as a Treatment for Ischemia-reperfusion Syndrome in Cardiogenic Shock Treated With Extracorporeal Life Support (ECMO/ECLS): A Randomized Pilot Study ECMORIX

Completed·—·N/A·NCT04886180·40 enrolled

COVID-191 trial

SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism

Terminated·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04584541·150 enrolled

Ovarian Reserve1 trial

Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients

Unknown status·HHadassah Medical Organization··NCT00930501·100 enrolled

Aortic Stenosis1 trial

Low Flow Low Gradient Aortic Stenosis Relevance of the (re)Search for a Contractile Reserve

Completed·RRennes University Hospital··NCT02727504·86 enrolled

2 more indications

Hidradenitis Suppurativa1 trial

Study of the Immunomodulation in the Hidradenitis Suppurativa and Evaluation of a New Therapeutic Strategy

Not yet recruiting·LLille Catholic University··NCT05208099·20 enrolled

Cognitive Disorder1 trial

The University of Hong Kong Neurocognitive Disorder Cohort

Unknown status·TThe University of Hong Kong··NCT03275363·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Blood tests. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blood tests compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blood tests. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rennes University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: RRennes University Hospital

Blood tests

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cerebrotendinous Xanthomatosis1 trial

Ischemia1 trial

COVID-191 trial

Ovarian Reserve1 trial

Aortic Stenosis1 trial

Hidradenitis Suppurativa1 trial

Cognitive Disorder1 trial

References

Drug Info

Quick Facts

Related News